Study #2024-1534
A phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed/refractory T-cell lymphoma (r/r TCL)
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, T-Cell
Study phase:
Phase II
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.